Literature DB >> 10348739

Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.

D McKenney1, K L Pouliot, Y Wang, V Murthy, M Ulrich, G Döring, J C Lee, D A Goldmann, G B Pier.   

Abstract

Vaccines based on preferential expression of bacterial antigens during human infection have not been described. Staphylococcus aureus synthesized poly-N-succinyl beta-1-6 glucosamine (PNSG) as a surface polysaccharide during human and animal infection, but few strains expressed PNSG in vitro. All S. aureus strains examined carried genes for PNSG synthesis. Immunization protected mice against kidney infections and death from strains that produced little PNSG in vitro. Nonimmune infected animals made antibody to PNSG, but serial in vitro cultures of kidney isolates yielded mostly cells that did not produce PNSG. PNSG is a candidate for use in a vaccine to protect against S. aureus infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348739     DOI: 10.1126/science.284.5419.1523

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  125 in total

1.  Synthetic peptide immunogens elicit polyclonal and monoclonal antibodies specific for linear epitopes in the D motifs of Staphylococcus aureus fibronectin-binding protein, which are composed of amino acids that are essential for fibronectin binding.

Authors:  M Huesca; Q Sun; R Peralta; G M Shivji; D N Sauder; M J McGavin
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 2.  Challenge of investigating biologically relevant functions of virulence factors in bacterial pathogens.

Authors:  R Moxon; C Tang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

3.  Correlation of Staphylococcus aureus icaADBC genotype and biofilm expression phenotype.

Authors:  H Rohde; J K Knobloch; M A Horstkotte; D Mack
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

4.  CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation.

Authors:  Torsten H Schroeder; Martin M Lee; Patrick W Yacono; Carolyn L Cannon; A Alev Gerçeker; David E Golan; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

5.  Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis.

Authors:  E B Hume; J J Dajcs; J M Moreau; R J O'Callaghan
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Biofilm formation by Staphylococcus epidermidis depends on functional RsbU, an activator of the sigB operon: differential activation mechanisms due to ethanol and salt stress.

Authors:  J K Knobloch; K Bartscht; A Sabottke; H Rohde; H H Feucht; D Mack
Journal:  J Bacteriol       Date:  2001-04       Impact factor: 3.490

7.  Capsule expression by bovine isolates of Staphylococcus aureus from Argentina: genetic and epidemiologic analyses.

Authors:  D O Sordelli; F R Buzzola; M I Gomez; L Steele-Moore; D Berg; E Gentilini; M Catalano; A J Reitz; T Tollersrud; G Denamiel; P Jeric; J C Lee
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

8.  Mutation of sarA in Staphylococcus aureus limits biofilm formation.

Authors:  Karen E Beenken; Jon S Blevins; Mark S Smeltzer
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

9.  icaR encodes a transcriptional repressor involved in environmental regulation of ica operon expression and biofilm formation in Staphylococcus epidermidis.

Authors:  Kevin M Conlon; Hilary Humphreys; James P O'Gara
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

Review 10.  Biofilm: the microbial "bunker" for intravascular catheter-related infection.

Authors:  Manuel Morales; Sebastián Méndez-Alvarez; Juana-Victoria Martín-López; Carmen Marrero; César O Freytes
Journal:  Support Care Cancer       Date:  2004-10       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.